The prevalence of myopia is rising. And today is when we need to act to protect a child’s precious vision from getting worse as they grow. MiSight® is the first and only FDA-approved* soft contact lens to slow the progression of myopia in children, aged 8-12 at the initiation of treatment.†*
To summarize, by the end of the 3-year randomized controlled portion of the 7-year MiSight® 1 day clinical trial, there was a 59% reduction in the rate of myopia progression, on average. †1
In the MiSight® webinar in CooperVision’s Online Success Center, you’ll find valuable information on the science around MiSight® 1 day and how you can discuss with your patients its efficacy in controlling the progression of myopia in children. Click here to sign up.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single-vision 1 day lens over a 3-year period.
* Only FDA approved soft contact lens designed for myopia control in the U.S.
1.Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci 2019,96.556-567
